Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3590 |
Name | gestational trophoblastic neoplasm |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | DOID:3598 DOID:14071 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer gestational trophoblastic neoplasm |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01535053 | Phase III | Leucovorin Dactinomycin Methotrexate | Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia | Completed | USA | GBR | CAN | 2 |
NCT03135769 | Phase II | Avelumab | Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (TROPHIMMUN) | Completed | FRA | 0 |
NCT04396223 | Phase Ib/II | Avelumab + Methotrexate | Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment (TROPHAMET) | Recruiting | FRA | 0 |
NCT05405192 | Phase II | Dostarlimab-gxly | Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia | Withdrawn | USA | 0 |
NCT06790706 | Phase II | AB154 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (IMMUNORARE5) | Not yet recruiting | FRA | 0 |